Pharma Co.'s Supply Chain Lies Caused Stock Drop, Suit Says
Keryx Biopharmaceuticals Inc. hid major problems with the supply chain for a new kidney disease treatment, leading to a 36 percent stock drop after production was delayed, shareholders alleged Friday in...To view the full article, register now.
Already a subscriber? Click here to view full article